Survival of patients as a function of MSKCC scores for sunitinib treatment in the 1st mRCC treatment line
2019
Abstract
The entry of tyrosine kinase inhibitors (TKI) into the 1st line of treatment for metastatic clear cell renal cell carcinoma (mRCC) has made a significant contribution to the treatment of our patients. Sunitinib was the first of these and still plays a crucial role in the treatment of the 1st line.
We have tried to analyze the results achieved by this treatment in the clinical practice of our departments. The efficacy and safety data of targeted mRCC treatment are gathered in the RENIS registry, which is able to provide a unique large-scale database from which treatment efficacy and prognostic data can be ascertained.
